Harmony Biosciences’ Four Key Pillars to Drive Value Creation
Harmony Biosciences reported a 17% year-over-year growth for WAKIX in the first quarter of 2026 and detailed four strategic priorities focused on long-term growth.
Harmony Biosciences reported a 17% year-over-year growth for WAKIX in the first quarter of 2026 and detailed four strategic priorities focused on long-term growth.
The FDA maintains its approval for the narcolepsy treatment in adults and recently expanded use in pediatric patients.
"These analyses further characterize the efficacy and safety profile of WAKIX and its broad clinical utility for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy."
Harmony Biosciences announced an increase in the usage of its narcolepsy drug Wakix (pitolisant) during the fourth quarter.
Read MoreHarmony Biosciences reported a 37% increase in net revenue in the third quarter, largely attributed to the growth in patient use of its narcolepsy drug Wakix.
Read MoreHarmony Biosciences announced new secondary endpoint data from its phase 2 signal-detection study evaluating pitolisant for the treatment of excessive daytime sleepiness in Prader-Willi syndrome.
Read MoreThe United States Patent and Trademark Office has denied a Petition for Reexamination concerning a patent covering the active ingredient in Wakix (pitolisant).
Read MoreHarmony Biosciences reported second-quarter business updates, showcasing an upswing in prescription demand for its narcolepsy drug, Wakix.
Read MoreThe study will further investigate pitolisant in children, adolescents, and adults with Prader-Willi syndrome experiencing excessive daytime sleepiness.
Read MoreThe approval makes pitolisant the first and only treatment drug approved in mainland China for narcolepsy.
Read MoreHarmony Biosciences presented safety and efficacy data from a phase 2 study evaluating pitolisant for the treatment of excessive daytime sleepiness in people with Prader-Willi syndrome at SLEEP 2023.
Read MoreThe phase 3 registrational INTUNE study will evaluate the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia.
Read MoreHarmony Biosciences will present the results, which it says it is “especially encouraged by,” during a poster presentation at SLEEP 2023 in Indianapolis.
Read MoreThe company reported business updates for the quarter ending March 31, noting continued momentum in its commercial business for Wakix, as well as in the advancement of its clinical development programs for pitolisant for the treatment of idiopathic hypersomnia.
Read MoreThe new CEO joined Harmony Biosciences as chief medical officer and executive vice president when the company was founded in 2017 and has been serving as interim president and CEO since Jan. 6.
Read MoreHarmony Biosciences announced an accelerated timeline for completing its phase 3 study evaluating pitolisant in adults idiopathic hypersomnia.
Read MoreThe European Medicines Agency approved Wakix for the treatment of narcolepsy in children over 6 years of age, with or without cataplexy.
Read MoreHarmony Biosciences spelled out next steps in its pursuit of pediatric exclusivity for WAKIX.
Read More